Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

HPRA recommendation could lead to ‘severe maternal morbidity’ – IMPS

By Catherine Reilly - 09th Mar 2020 | 23 views

Implementing a recommendation approved by the Health Products Regulatory Authority (HPRA) could lead to “sub-optimal control” of hyperemesis gravidarum (HG) and “potentially severe maternal morbidity”, according to the Irish Medicines in Pregnancy Service (IMPS).

The IMPS, based at the Rotunda Hospital, noted that in late 2019 the marketing authorisation holders (MAH) for ondansetron (Zofran) wrote to healthcare professionals regarding its safety during the first trimester of pregnancy.

The communication followed recommendations from the European Medicines Agency (EMA) and HPRA, which included that ondansetron should not be used during the first trimester. This recommendation applied to ondansetron’s licensed indications, which does not include HG, noted the IMPS.

HG is a complication of pregnancy characterised by severe, protracted nausea and vomiting. In its position statement, the IMPS recommended that ondansetron should remain a treatment option for women with HG, where first-line agents have not been effective. Women should be adequately counselled on benefits and potential risks.

The IMPS did not consider that available data supported the conclusion that ondansetron caused congenital anomalies.

An IMPS spokesperson said its statement offered “pragmatic recommendations from the perspective of healthcare professionals”. A HPRA spokesperson said the EMA’s safety committee examined ondansetron in its licensed uses. This followed a review of new safety data, which reported “a small but increased risk” of orofacial malformations linked to the drug’s use in the first trimester.

As ondansetron is not licensed for use in HG in the EU, the EMA committee did not conduct a benefit-risk assessment in this off-label indication.

Off-label use was a matter of clinical judgement and prescribers “can refer to clinical guidelines” if treatment with ondansetron is considered for HG, stated the HPRA spokesperson. The HPRA “fully agrees with the principle that the risks to the unborn child when taking a medicine during pregnancy have to be weighed against the risks to the mother and child of not taking the medicine”.

Leave a Reply

Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read